anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a skin medicine for external use, containing an active oxygen remover and/or an antioxidant and further a complex of a protein or its hydrolyzate with a phospholipid in combination, capable of suppressing formation of peroxides in a product and excellent in aging preventive and skin roughening improving effects. CONSTITUTION:A skin medicine for external use is obtained by including an active oxygen remover (e.g. superoxide dismutase, mannitol or beta-carotene) and/or an antioxidant (e.g. vitamin B s, vitamin C or glutathione) and further a protein (e.g. collagen)-phospholipid (e.g. hydrogenated soybean lecithin) complex used in combination. The resultant skin medicine for external use is capable of suppressing formation of peroxides, stable with time and excellent in skin aging preventive and roughening improving effects. The above-mentioned complex is preferably blended in an amount of about 0.05-5wt.% in the medicine for the external use to sufficiently improve effects of the active oxygen remover and/or the antioxidant and prevent stickiness. The active oxygen remover and the antioxidant are preferably blended in an amount of about 0.001-3.0wt.%.
The present invention provides improved cell delivery compositions. In particular, the invention provides biocompatible endosomolytic agents. In a preferred embodiment, the endosomolytic agents are also biodegradable and can be broken down within cells into components that the cells can either reuse or dispose of. In one aspect, the present invention provides endosomolytic agents capable of effecting the lysis of an endosome in response to a change in pH, and methods for effecting the lysis of an endosome. These inventive endosomolytic agents obviate the need for known agents (i.e., chloroquine, fusogenic peptides, inactivated adenoviruses and polyethyleneimine) that can burst endosomes and have negative effects on cells. In another aspect, the present invention provides cell delivery compositions comprising an endosomolytic component that is capable of effecting the lysis of the endosome in reponse to a change in pH, and an encapsulating, or packaging, component capable of packaging a therapeutic agent to be delivered to cellular or subcellular components.
This study aimed to explore the effects of miR-129-5p on inflammation and nucleus pulposus (NP) cell apoptosis in rats with intervertebral disc degeneration (IVDD) through the c-Jun N-terminal kinase (JNK) signaling pathway. A total of 20 rats were randomly divided into control group (n=10) or IVDD group (n=10). The mRNA expressions of miR-129-5p and apoptosis index Fas in IVDD tissues were determined using RT-PCR. NP cell apoptosis rate was detected via TUNEL assay. NP cells were extracted from IVDD tissues for primary culture. Subsequently, the cells were transfected with miR-129-5p inhibitor or mimic to inhibit or overexpress miR-129-5p, respectively. Furthermore, the changes in the JNK pathway indexes and apoptosis indexes were detected using Western blotting. In IVDD group, the expression of miR-129-5p was significantly down-regulated, while the transcriptional level of Fas was up-regulated compared with those in control group. Pearson correlation analysis revealed a negative correlation between the expressions of miR-129-5p and Fas mRNA (r=-0.75, P<0.05). IVDD group exhibited significantly higher levels of serum TNF-α, IL-6 and IL-1 than control group. Subsequent TUNEL assay indicated that the apoptosis rate was evidently higher in IVDD group (60.6%) than control group (2.5%). The results of Western blotting showed that the protein expressions of JNK1, JNK2 and Fas remarkably rose in IVDD group compared with those in control group. However, they declined remarkably in miR-129-5p mimic group compared with those in control group. Furthermore, such trends were significantly reversed in miR-129-5p inhibitor group. MiR-129-5p was significantly down-regulated in IVDD, whose overexpression has anti-inflammatory and anti-apoptotic effects.
From Day 0 to Day 38, participants will receive tamoxifen orally once a day. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
The goal of this project is to pilot test different levels of behavioral intervention for patients diagnosed with FAP who are presenting for pediatric gastroenterology care. Patients are screened during their medical visit. Those with more than minimal levels of functional disability (Functional Disability Inventory (FDI) score \>7), receive Enhanced Usual Care (EUC), brief pain-focused psychoeducation administered as part of their medical visit. As part of EUC, patients receive access to a web module for home use that reiterates educational material and offers relaxation training tools for home practice (i.e., audio recordings). Two weeks following EUC, patient outcomes are re-assessed with a focus on pain-related disability. Those who fail to respond to EUC (i.e., FDI remains \>7) are invited to complete the next phase of the study. Eligible participants undergo a baseline assessment consisting of a diagnostic interview and child measures pertaining to pain, anxiety, depressive symptoms, and pain-related worries. Caregivers complete forms about their child's pain history, child disability, and child worries. Caregivers also complete a form about their own stress symptoms. After baseline assessment, patients are randomized to medical treatment as usual (TAU) or ADAPT, a tailored CBT delivered by a trained psychologist. ADAPT content differs based on the individual needs of the patient (i.e., all patients receive 4 pain-focused coping skills sessions, and those who present with clinical levels of anxiety receive 2 additional sessions to address anxiety symptoms). Participants complete 4 or 6 sessions (2 in person sessions and 2-4 web modules with phone support). Approximately six weeks after randomization, the patient and caregiver undergo follow-up assessment to assess pain, anxiety, and disability. It is hypothesized that youth who participate in ADAPT will have lower average pain rating scores, less pain-related functional disability, and lower levels of anxiety symptoms (if elevated) at post-assessment as compared to youth receiving medical TAU.
FIELD: medicine, virology. SUBSTANCE: method involves administration to patient leukocyte serine protease inhibitor (LSPI) or its derivative at the dose that is sufficient for infection suppression. Derivative of LSPI is taken from LSPI Phe-72 mutein or LSPI Gly-20 mutein, or LSPI Gly-72 mutein, LSPI Val-72 mutein, or LSPI Phe-25 mutein, or LSPI Gly-25 mutein, or LSPI Val-25 mutein. Activity of leukocyte serine is suppressed. Amino acid sequence of isolated protease inhibitor and nucleotide sequence of nucleic acid that encodes this amino acid sequence are defined. Then nucleic acid that is able to direct host-organism to production of protein with defined amino acid sequence is prepared. Nucleic acid is cloned into vector that can be transferred and replicated in host-microorganism. Vector has operation members for nucleic acid. Vector is transferred in host-microorganism that is able to express serine protease inhibitor. Invention can be used for treatment of patients with retroviral infections, in part, human immunodeficiency virus (HIV) and provides new methods of prophylaxis and treatment of mammalian with retroviral infections. EFFECT: improved method of an inhibitor producing, enhanced effectiveness of inhibition. 12 cl, 9 tbl, 2 dwg, 11 ex
Ventricular tachycardia (VT), and its occurrence, is still one of the main reasons for sudden cardiac death and, therefore, for increased mortality and morbidity foremost in patients with structural heart [Kahle A-K, Jungen C, Alken F-A, Scherschel K, Willems S, Pürerfellner H et al. Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium. Europace 2022;24:538-51]. Catheter ablation has become a safe and effective treatment option in patients with recurrent VT [Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm 2020;17:e2-154]. Previous and current guidelines provide guidance on indication for VT ablation and risk assessment and evaluation of underlying disease. However, no uniform recommendation is provided regarding procedural strategies, timing of ablation, and centre setting. Therefore, these specifics seem to differ largely, and recent data are sparse. This physician-based European Heart Rhythm Association survey aims to deliver insights on not only infrastructural settings but also procedural specifics, applied technologies, ablation strategies, and procedural endpoints. Therefore, these findings might deliver a real-world scenario of VT management and potentially are of guidance for other centres.
HSV infection in patients with AIDS is often associated with skin sores and frequent recurrences. Treatment with the drug acyclovir results in healing for most patients, but repeated treatment sometimes results in resistance of the virus to acyclovir. Thus, when this happens, other treatments need to be used. Trifluridine is an antiviral drug that is used for the treatment of Herpes infections that occur in the eye. This study attempts to determine if trifluridine is useful for treating HSV sores that have not healed after treatment with acyclovir.

Patients receive at least 10 days (and up to 42 days) of treatment with topical trifluridine. Trifluridine is applied in a thin fluid layer that overlaps the edges of the lesion. Polymyxin B sulfate/bacitracin zinc ointment is then applied over the trifluridine. Lesions are covered by a nonabsorbent dressing. Medication is applied every 8 hours.
This is an open-label, single-center, single-dose, randomized, two-way crossover study in healthy volunteers. Each Subject will complete Screening, Baseline, Treatment, and Follow-up Phases.

After a Screening Phase, Subjects meeting entry criteria will be admitted to the clinical research unit (CRU) and undergo baseline assessments. Subjects will be randomly assigned in a 1:1 ratio to 1 of 2 treatment sequences (IV furosemide followed by SC or vice versa). Subjects will remain domiciled in the CRU for each treatment period which will be about 12-hours. After final assessments are performed, Subjects may be discharged from the CRU if safety parameters are acceptable to the Investigator and return to the CRU after a 3-day washout period to receive the second treatment sequence. The Follow-up Phase will occur 24-48 hours after discharge from the CRU following treatment sequence 2, completing Subjects' study participation.
PROBLEM TO BE SOLVED: To prepare the subject aerosol agent having strong and persistent cooling properties without causing problems such as sagging when jet coated and useful for blows, etc., by combining a stock solution composition with a propellant at a specific weight ratio. SOLUTION: This aerosol agent comprises (A) a stock solution composition having 350-500,000cSt viscosity and (B) a propellant of a liquefied gas (e.g. n-butane) at (50:50) to (5:95) weight ratio of the ingredients A:B. A pharmacodynamically effective ingredient (e.g. indometacin) is preferably formulated in the ingredient A. For example, hydroxypropyl cellulose, diisopropyl adipate or ethanol is preferably used as the ingredient A.
The present invention relates to a traditional Chinese medicine preparation for treating threatened abortion, which takes more than 10 Chinese herbal medicines of Chinese taxillus twig, himalayan teasel root, south dodder seed, heterophylly falsestarwort root etc. as the raw materials. The present invention has the effects of invigorating kidney, benefiting qi and nourishing blood for preventing miscarriage. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine preparation to treat threatened abortion. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
The invention relates to a tablet for cleaning dental prosthesis and orthodontic appliances in ultrasonic baths containing a solid acidic compound which is readily soluble in water and a surfactant which is readily soluble in water, this containing an enzyme. This enzyme advantageously consists of a pepsin. As an alternative to this it is also possible to use a papain. A mixture of these substances can also be used advantageously. The invention can also be combined with processes and measures known per se. Thus, an acidic compound which contains an acidic phosphate and/or citric acid can be used. The acidic phosphate can also be a urea phosphate. It is furthermore particularly advantageous for the surfactant to be non-ionic. It is furthermore possible to use as surfactant an ethoxylate or a fatty alcohol ethoxylate. It is furthermore expedient to use a surfactant which has at least five ethylene oxide units in the molecule and/or in which the fatty alcohol of the surfactant contains ten to twenty C atoms in the molecule.
Patients with EGFR T790M or rare activating mutation receive osimertinib (AZD9291) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo radiologic evaluation throughout the trial, ECHO or multigated acquisition scan (MUGA) during screening, and biopsy and collection of blood samples on trial and at end of treatment.
The objective of this randomized, controlled pilot study is to evaluate the effect of Microcurrent therapy on pain and physical function in patients with osteoarthritis of the knee. The secondary objective is to compare the effects of different currents. Patients will be randomized to four groups: Group 1 and 2 both will receive Microcurrent Therapy, but different currents will be used. Group 3 will receive treatment with the Microcurrent treatment apparatus, but without any current. Group 4 will be a control group without specific intervention.

Group 1, 2 and 3 will receive 10 sessions of treatment in a treatment phase of four weeks. Assessments for group 1, 2, and 3 will be scheduled for screening (T0), at the first day of treatment (T1), at the end of treatment (T2) and three months after the end of treatment (T3). Group 4 will be assessed at a screening visit T0, at T1, at T2 (approximately 21 days after T1), and at T3 (three months after T2). Patients will be recruited based on the records of the clinic.
OBJECTIVE: To assess diet quality and its association with body and biochemical parameters in patients who underwent Roux-en-Y gastric bypass (RYGB).
METHODS: Prospective observational study with individuals of both sexes subjected to RYGB. Body composition, biochemical parameters, and diet quality were assessed before and six months after RYGB. Diet quality was assessed by the Healthy Eating Index (HEI). Data were analyzed by the paired t-test or Wilcoxon signed-rank test, with a significance level of 5%. Spearman's correlation and simple linear regression were performed between variables.
RESULTS: The final sample included 34 patients. Their diet was classified as poor before and 6 mo after RYGB. BMI, fat mass, fat-free mass, waist perimeter, serum total protein, transthyretin, alpha-1-acid glycoprotein, and C-reactive protein decreased significantly (P < 0.05). Variations in the HEI score and caloric intake were associated with serum albumin and transthyretin (P < 0.05).
CONCLUSION: Poor diet quality was present before and six months after RYGB, and the study data suggest that poor diet quality is associated to a risk of loss of lean body mass and visceral protein six months after RYGB.
The energy needs of tubular epithelial components, especially proximal tubular epithelial cells (PTECs), are high and they heavily depend on aerobic metabolism. As a result, they are particularly vulnerable to various injuries caused by factors such as ischemia, proteinuria, toxins, and elevated glucose levels. Initial metabolic and phenotypic changes in PTECs after injury are likely an attempt at survival and repair. Nevertheless, in cases of recurrent or prolonged injury, PTECs have the potential to undergo a transition to a secretory state, leading to the generation and discharge of diverse bioactive substances, including transforming growth factor-β, Wnt ligands, hepatocyte growth factor, interleukin (IL)-1β, lactic acid, exosomes, and extracellular vesicles. By promoting fibroblast activation, macrophage recruitment, and endothelial cell loss, these bioactive compounds stimulate communication between epithelial cells and other interstitial cells, ultimately worsening renal damage. This review provides a summary of the latest findings on bioactive compounds that facilitate the communication between these cellular categories, ultimately leading to the advancement of tubulointerstitial fibrosis (TIF).
NEW MATERIAL:A compound shown by the formula I (R is group shown by the formula II - formula IV; R<1> is H, or -SO3Na). EXAMPLE:A compound shown by the formula V. USE:An antifungal agent such as mildewcide, antitrichophytial agent, an agent to destroy fungi belonging to the genus Candida, etc. PREPARATION:For example, the body wall of Holothuria pervicax is extracted with a lower alcohol such as methanol, etc. under heating, the extract is desalted, separated and purified by silica gel chromatography, etc. to give pervicoside A (namely, compound shown by the formula V) wherein the group R<1> of the formula I is -SO3Na, and the group R is shown by the formula II, pervicoside B wherein the group R is shown by the formula III, and pervicoside C wherein the group R is shown by the formula IV. Pervicosides A-C are desulfated to give compounds wherein the group R<1> of the formula I is H.
EOI block is performed by placing the US probe in paramedian sagittal orientation at the T6-7 level and visualizing the external oblique and intercostal muscles. Local anesthetics inject the under the external oblique muscle.
PCT No. PCT/FR94/01132 Sec. 371 Date Mar. 27, 1996 Sec. 102(e) Date Mar. 27, 1996 PCT Filed Sep. 28, 1994 PCT Pub. No. WO95/09207 PCT Pub. Date Apr. 6, 1995Block copolymers denoted by AB from acrylic or methacrylic acid, the corresponding blocks being denoted by A, and from alkyl acrylate or methacrylate with the alkyl chain being C1-C10, the corresponding blocks being denoted by B. Said copolymer blocks are used as wetting and/or dispersing agents for solid particles in an essentially organic medium consisting of a solvent or a mixture of solvents solubilizing the block B. The invention also concerns solid particle dispersions using the above-defined block copolymers. It also concerns compositions, in particular cosmetic compositions, containing said dispersions.
Patients randomized to this treatment group will receive lumbar manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
The present invention provides a traditional Chinese medicine preparation for treating importence, which is the prepared slice comprising the following medicinal materials: 20-180 parts by weight of Astragalus root; 15-30 parts by weight of Chinese angelica; 15-30 parts by weight of pilose asiabell root or 15-20 parts by weight of ginseng; 15-30 parts by weight of white peony root; 6-15 parts by weight of actynolin; 2-3 parts by weight of centipede; 10-15 parts by weight of shorthorned epimedium herb; 10-15 parts by weight of dodder seed; 15-30 parts by weight of common cnidium fruit; 6-15 parts by weight of chuanxiong rhizome; 6-15 parts by weight of nutgrass galingale rhizome; 3-5 parts by weight of powdered antler or 0.5-1.5 parts by weight of hairy antler; and 6-10 parts by weight of liquorice. The Chinese medicine preparation for treating importenance according to the invention applies the method of general nourishment on the basis of the theory of traditional Chinese medicine forregulating the dysfunction of meridian of human organ and the unsmooth running of qi-blood and body fluid. The invention overcomes the defect of unremarkable effect when the method of temperature com pensation is singly applied for treating the asynodia according to the traditional Chinese medicine. Simultaneously the side effect caused by singly adopting vasodilation or hormone therapy according to the western medicine. The traditional Chinese medicine of the invention has the characteristics of quick curative effect, no toxic or side effect, flexible theory and radical treatment. Simultaneously according to the principle of treating the root of the disease in the theory of traditional Chinese medicine, the medicine is added or reduced according to the illness state on the basis of general nourishment for adopting the symptoms of different patients or the illness states of a same patient in different periods.
If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a PR or HI after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
Lifestyle modification program focused on physical activity and diet. Diet recommendations in line with the AHA's guidelines focusing on foods rather than nutrients. Emphasis will be placed on awareness of the risk of overeating associated with the consumption of energy-dense foods (fat, added sugar or both). Dieticians will closely interact with participants and will not recommend a daily energy deficit greater than 500 kcal. Participants will have constant access to the dieticians and bi-monthly appointment will be required for the first year of the study to tailor recommendations to the participants. The physical activity/exercise component will be under the supervision of a kinesiologist and will aim at 160 minutes per week of moderate intensity endurance-exercise (mainly brisk walking) tailored to the participants' preferences and habits. Following the first year, participants will meet a dietician and a kinesiologist every month for the next two years (maintenance period).
A medication dispensing and compliance monitoring system is described. The system includes a dispenser unit which holds a tray containing an array of sequentially ordered medication canisters and a mobile computing device physically incorporated into the dispenser unit. The mobile computing device, such as a cell phone, acts as a communications link and contains processing, memory, and user interface capabilities of the system. Each medication canister is dispensed by the system at a prescribed time, and contains a single dose of one or more medications. Sensors within the dispenser create data documents times wherein medications are dispensed, which can be uplinked to remote parties, such as healthcare providers, caretakers, and family members. Coupling with patient physiologic monitoring devices is also provided. A novel loading tray for accurately loading a plurality of prescribed medications into each medication canister is also disclosed.